4 months BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer Zacks
The European Commission approves Bristol Myers’ Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer.
XThe European Commission approves Bristol Myers’ Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer.
XThe Stock Market News is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live qoute and chart technical analysis, opinion, price forecast on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.